Core C will play a central and critical role in this P01. Three types of services will be provided. These are: A. Biospecimen Procurement, Handling and Distribution: A major function of the CORE will be to serve as a central site for receiving, cataloging, storing and redistributing samples from Nordic countries to the NRH. In addition, samples will then be sent to MDACC for redistribution and analyses there. B. Pathology Services: The second main objective will involve a coordinated effort by the Nordic pathology team headed by Dr. Reith and Dr. Adel EI-Naggar at MDACC who will implement standardized criteria for biomarker scoring and evaluation. They will coordinate and provide professional services for proper handling and processing of histopathologic materials. C. Pharmacology Services: This part of Core C will provide a number of pharmacology services that include analyses of plasma drug levels of Celecoxib and EKB-569 as well as eicosanoid metabolism within clinical biopsy specimens and animal tissues. Eicosanoids will be determined using a highly specialized tandem mass spectrometry procedure developed by the Director of this Core, Dr. Newman. In addition, mass spectrometry analyses of peptides will provide support to Dr. Mao's proteomics research in Project 3. As the clinical trial progresses to attain the targeted sample size, more Core effort will be required in the preparation and distribution of tissue sections for the translational research projects. The role of this Core will become increasingly important because proposed studies and further progress in the field of carcinogenesis research may identify new cellular, biochemical, or molecular genetic markers of interest. These will need to be tested and expanded using the tissue samples obtained through this project.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
William Jr, William N; Papadimitrakopoulou, Vassiliki; Lee, J Jack et al. (2016) Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol 2:209-16
Wan, Y; Datta, S; Conklin, D J et al. (2015) Variable selection models based on multiple imputation with an application for predicting median effective dose and maximum effect. J Stat Comput Simul 85:1902-1916
Aristizabal, Paula; Singer, Jenelle; Cooper, Renee et al. (2015) Participation in pediatric oncology research protocols: Racial/ethnic, language and age-based disparities. Pediatr Blood Cancer 62:1337-44
Mak, Milena P; William Jr, William N (2014) Targeting the epidermal growth factor receptor for head and neck cancer chemoprevention. Oral Oncol 50:918-23
William Jr, William N; Papadimitrakopoulou, Vassiliki A (2013) Optimizing biomarkers and endpoints in oral cancer chemoprevention trials. Cancer Prev Res (Phila) 6:375-8
William Jr, William N (2012) Oral premalignant lesions: any progress with systemic therapies? Curr Opin Oncol 24:205-10
Saintigny, Pierre; Zhang, Li; Fan, You-Hong et al. (2011) Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila) 4:218-29
Diao, Lixia; Clarke, Charlotte H; Coombes, Kevin R et al. (2011) Reproducibility of SELDI Spectra Across Time and Laboratories. Cancer Inform 10:45-64
Lee, J Jack; Wu, Xifeng; Hildebrandt, Michelle A T et al. (2011) Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) 4:185-93
Boyle, Jay O; Gumus, Zeynep H; Kacker, Ashutosh et al. (2010) Effects of cigarette smoke on the human oral mucosal transcriptome. Cancer Prev Res (Phila) 3:266-78

Showing the most recent 10 out of 54 publications